6.30
1.55%
+0.0962
Precipio Inc stock is currently priced at $6.30, with a 24-hour trading volume of 2,331.
It has seen a +1.55% increased in the last 24 hours and a -5.49% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.15 pivot point. If it approaches the $6.38 resistance level, significant changes may occur.
Precipio Inc Stock (PRPO) Financials Data
Precipio Inc (PRPO) Revenue 2023
PRPO reported a revenue (TTM) of $13.26 million for the quarter ending September 30, 2023, a +40.22% rise year-over-year.
Precipio Inc (PRPO) Net Income 2023
PRPO net income (TTM) was -$9.07 million for the quarter ending September 30, 2023, a +25.17% increase year-over-year.
Precipio Inc (PRPO) Cash Flow 2023
PRPO recorded a free cash flow (TTM) of -$5.30 million for the quarter ending September 30, 2023, a +33.27% increase year-over-year.
Precipio Inc (PRPO) Earnings per Share 2023
PRPO earnings per share (TTM) was -$7.52 for the quarter ending September 30, 2023, a +27.62% growth year-over-year.
Precipio Inc Stock (PRPO) Latest News
Precipio Announces Year end 2023 Shareholder Update Call
GlobeNewswire Inc.
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
GlobeNewswire Inc.
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
GlobeNewswire Inc.
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
GlobeNewswire Inc.
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
GlobeNewswire Inc.
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
GlobeNewswire Inc.
About Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Cap:
|
Volume (24h):